Biodegradable ocular implants

• US 4,853,224 A
• Filed: 12/22/1987
• Issued: 08/01/1989
• Est. Priority Date: 12/22/1987
• Status: Expired due to Term

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Visionex Inc.
• Inventors: Wong, Vernon G.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): HORNE, LEON
• Application Number:
  US07/136,402
• Time in Patent Office: 588 Days
• Field of Search: 424/427
• US Class Current: 424/427
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

Microencapsulated drugs are employed for introduction into the chambers of the eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Claims

1. A method for treating an eye condition which comprises:

implanting at least one of the anterior or posterior chamber of an eye at least one microencapsulated drug as particles of not greater than about 300 micrometers, said particles comprising said drug and a pharmacologically acceptable biodegradable polymer which is degraded in the eye.

2. A method according to claim 1, wherein said polymer is a condensation polymer.

3. A method according to claim 2, wherein said polymer is a polyester.

4. A method according to claim 3, wherein said polyester comprises an hydroxyaliphatic carboxylic acid monomer.

5. A method according to claim 4, wherein said hydroxyaliphatic carboxylic acid is lactic acid.

6. A method according to claim 1, wherein said particle comprises a pharmacologically acceptable buffering agent.

7. A method according to claim 1, wherein said drug is a cytotoxic agent.

8. A method according to claim 1, wherein said steroid is hydrocortisone or a pharmacologically acceptable ester.

9. A method according to claim 7, wherein said cytotoxic agent is methotrexate.

10. A method according to claim 1, wherein an effective dosage for treatment of said condition is maintained in said chamber for at least one month.

11. A method according to claim 10, wherein said particle is of an average size in the range of 10 to 250 micrometers.

12. A method according to claim 1, wherein said drug is a growth factor.